Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$17.24
-0.60-3.36%
À la fermeture: -
$17.24
0.000.00%
Après les heures de négociation: 4:31 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
RXO Inc a un objectif de cours consensus de $19.95, basé sur les évaluations des 23 analystes. Le plus élevé est de $31 attribué par Wells Fargo le novembre 11, 2024, et le plus bas est de $13 attribué par Susquehanna le mars 26, 2025. Les 3 dernières évaluations d'analystes ont été publiées par Stifel, Goldman Sachs et JP Morgan le octobre 10, 2025, octobre 9, 2025 et octobre 8, 2025. Avec un objectif de cours moyen de $16 entre Stifel, Goldman Sachs et JP Morgan, il y a une variation implicite de -7.19% downside pour RXO Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Stifel
Goldman Sachs
JP Morgan
UBS
Barclays
1calculé à partir des notes des analystes
Notes d'analystes pour RXO
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/10/2025 | -1.39% | Stifel | $14 → $17 | Maintains | Hold | |||
10/09/2025 | -12.99% | Goldman Sachs | $17 → $15 | Maintains | Neutral | |||
10/08/2025 | -7.19% | JP Morgan | $15 → $16 | Maintains | Underweight | |||
10/03/2025 | -1.39% | UBS | $15 → $17 | Maintains | Neutral | |||
08/12/2025 | -1.39% | Barclays | $18 → $17 | Maintains | Overweight | |||
08/08/2025 | -7.19% | B of A Securities | $18 → $16 | Maintains | Neutral | |||
08/08/2025 | -12.99% | UBS | $14 → $15 | Maintains | Neutral | |||
07/08/2025 | -18.79% | JP Morgan | $15 → $14 | Maintains | Underweight | |||
07/07/2025 | 21.81% | Morgan Stanley | $23 → $21 | Maintains | Equal-Weight | |||
05/21/2025 | 4.41% | Citigroup | $15 → $18 | Maintains | Neutral | |||
05/16/2025 | 4.41% | B of A Securities | $15 → $18 | Maintains | Neutral | |||
05/08/2025 | -18.79% | UBS | $24 → $14 | Maintains | Neutral | |||
05/08/2025 | 4.41% | Goldman Sachs | $21 → $18 | Maintains | Neutral | |||
05/08/2025 | -18.79% | Stifel | $24 → $14 | Maintains | Hold | |||
05/08/2025 | -12.99% | Wells Fargo | $20 → $15 | Maintains | Equal-Weight | |||
04/24/2025 | 10.21% | Truist Securities | $24 → $19 | Maintains | Buy | |||
04/11/2025 | 16.01% | Jefferies | $26 → $20 | Maintains | Buy | |||
04/10/2025 | 21.81% | Goldman Sachs | $24 → $21 | Maintains | Neutral | |||
04/08/2025 | -12.99% | Citigroup | $23 → $15 | Maintains | Neutral | |||
04/04/2025 | — | Oppenheimer | — | Downgrade | Outperform → Perform | |||
04/02/2025 | 27.61% | Barclays | $24 → $22 | Maintains | Overweight | |||
03/27/2025 | 16.01% | Wells Fargo | $22 → $20 | Maintains | Equal-Weight | |||
03/26/2025 | -24.59% | Susquehanna | $18 → $13 | Maintains | Negative | |||
03/13/2025 | 39.21% | Truist Securities | → $24 | Initiates | → Buy | |||
02/06/2025 | 39.21% | Goldman Sachs | $28 → $24 | Maintains | Neutral | |||
02/06/2025 | 39.21% | Stifel | $27 → $24 | Maintains | Hold | |||
02/06/2025 | 45.01% | Morgan Stanley | $27 → $25 | Maintains | Equal-Weight | |||
01/23/2025 | 56.61% | Stifel | $26 → $27 | Maintains | Hold | |||
01/17/2025 | 74.01% | Barclays | $32 → $30 | Maintains | Overweight | |||
01/15/2025 | — | Benchmark | — | Reiterates | Hold → Hold | |||
01/10/2025 | 74.01% | Jefferies | $33 → $30 | Maintains | Buy | |||
01/07/2025 | 62.41% | Wells Fargo | $31 → $28 | Maintains | Equal-Weight | |||
11/18/2024 | 68.21% | Goldman Sachs | → $29 | Reinstates | → Neutral | |||
11/12/2024 | -30.39% | Susquehanna | $16 → $12 | Maintains | Negative | |||
11/12/2024 | 91.42% | Citigroup | $33 → $33 | Downgrade | Buy → Neutral | |||
11/11/2024 | 79.81% | Wells Fargo | → $31 | Reinstates | Equal-Weight → Equal-Weight | |||
10/15/2024 | — | Benchmark | — | Reiterates | → Hold | |||
10/09/2024 | 91.42% | Citigroup | → $33 | Initiates | → Buy | |||
09/26/2024 | -7.19% | Susquehanna | $20 → $16 | Maintains | Negative | |||
09/17/2024 | 79.81% | Oppenheimer | $31 → $31 | Reiterates | Outperform → Outperform | |||
08/15/2024 | 16.01% | Susquehanna | $14 → $20 | Maintains | Negative | |||
08/13/2024 | 79.81% | Jefferies | $33 → $31 | Maintains | Buy | |||
08/13/2024 | — | Benchmark | — | Reiterates | → Hold | |||
08/12/2024 | 50.81% | Morgan Stanley | $19 → $26 | Maintains | Equal-Weight | |||
08/09/2024 | 85.61% | Barclays | $30 → $32 | Maintains | Overweight | |||
08/08/2024 | 62.41% | TD Cowen | $23 → $28 | Maintains | Hold | |||
08/08/2024 | 50.81% | JP Morgan | $25 → $26 | Maintains | Underweight | |||
08/08/2024 | 79.81% | Oppenheimer | $22 → $31 | Maintains | Outperform | |||
08/08/2024 | 79.81% | UBS | $22 → $31 | Maintains | Neutral | |||
07/16/2024 | 74.01% | Barclays | $24 → $30 | Maintains | Overweight | |||
07/09/2024 | 45.01% | JP Morgan | $16 → $25 | Maintains | Underweight | |||
06/12/2024 | — | Benchmark | — | Reiterates | → Hold | |||
05/15/2024 | — | Raymond James | — | Reinstates | → Market Perform | |||
05/06/2024 | 27.61% | Stephens & Co. | $22 → $22 | Reiterates | Equal-Weight → Equal-Weight | |||
04/19/2024 | — | Benchmark | — | Reiterates | → Hold | |||
03/26/2024 | -7.19% | Susquehanna | $15 → $16 | Maintains | Negative | |||
03/25/2024 | -7.19% | Susquehanna | $15 → $16 | Maintains | Negative | |||
02/13/2024 | 27.61% | Oppenheimer | $23 → $22 | Maintains | Outperform | |||
02/09/2024 | -12.99% | Susquehanna | $18 → $15 | Maintains | Negative | |||
02/08/2024 | 27.61% | B of A Securities | $25 → $22 | Downgrade | Buy → Neutral | |||
01/16/2024 | 45.01% | B of A Securities | $21 → $25 | Maintains | Buy | |||
01/10/2024 | 27.61% | Stifel | $20 → $22 | Maintains | Hold | |||
01/10/2024 | 33.41% | Vertical Research | → $23 | Downgrade | Buy → Hold | |||
10/16/2023 | -1.39% | Stifel | $19 → $17 | Maintains | Hold | |||
10/11/2023 | -7.19% | JP Morgan | $17 → $16 | Downgrade | Neutral → Underweight | |||
10/03/2023 | -24.59% | Susquehanna | $14 → $13 | Maintains | Negative | |||
10/02/2023 | 4.41% | Morgan Stanley | $20 → $18 | Maintains | Equal-Weight | |||
08/31/2023 | -18.79% | Susquehanna | $19 → $14 | Downgrade | Neutral → Negative | |||
08/07/2023 | 39.21% | Oppenheimer | → $24 | Reiterates | Outperform → Outperform | |||
08/03/2023 | 16.01% | Morgan Stanley | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight | |||
08/03/2023 | 10.21% | Stephens & Co. | $23 → $19 | Maintains | Equal-Weight | |||
07/12/2023 | 10.21% | Wolfe Research | → $19 | Downgrade | Peer Perform → Underperform | |||
07/06/2023 | 16.01% | Morgan Stanley | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight | |||
06/09/2023 | 16.01% | Susquehanna | → $20 | Initiates | → Neutral | |||
05/24/2023 | 56.61% | Barclays | → $27 | Initiates | → Overweight | |||
05/04/2023 | 21.81% | Wells Fargo | $22 → $21 | Maintains | Equal-Weight | |||
04/04/2023 | — | Benchmark | — | Initiates | → Hold | |||
02/27/2023 | 27.61% | Cowen & Co. | → $22 | Initiates | → Market Perform | |||
02/09/2023 | 33.41% | UBS | $20 → $23 | Maintains | Neutral | |||
02/09/2023 | 27.61% | Goldman Sachs | $20 → $22 | Maintains | Neutral | |||
02/09/2023 | 39.21% | Oppenheimer | $21 → $24 | Maintains | Outperform | |||
02/08/2023 | 16.01% | Stephens & Co. | → $20 | Maintains | Equal-Weight | |||
01/11/2023 | -1.39% | Stifel | $20 → $17 | Downgrade | Buy → Hold | |||
01/09/2023 | 10.21% | JP Morgan | → $19 | Initiates | → Neutral | |||
12/20/2022 | 4.41% | Wells Fargo | → $18 | Initiates | → Equal-Weight | |||
12/09/2022 | 16.01% | UBS | → $20 | Initiates | → Neutral | |||
12/09/2022 | 16.01% | Morgan Stanley | → $20 | Initiates | → Equal-Weight | |||
12/06/2022 | 45.01% | Jefferies | → $25 | Initiates | → Buy | |||
12/05/2022 | — | Raymond James | — | Initiates | → Market Perform | |||
11/30/2022 | 27.61% | B of A Securities | → $22 | Initiates | → Buy | |||
11/22/2022 | 21.81% | Oppenheimer | → $21 | Initiates | → Outperform | |||
11/22/2022 | 16.01% | Goldman Sachs | → $20 | Initiates | → Neutral | |||
11/21/2022 | 56.61% | Vertical Research | → $27 | Initiates | → Buy | |||
11/10/2022 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
11/04/2022 | 16.01% | Stifel | → $20 | Initiates | → Buy |
FAQ
Quel est le cours indicatif de l'action RXO (RXO) ?
Le dernier objectif de prix pour RXO (NYSE:RXO) a été rapporté par Stifel le octobre 10, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $17.00 s'attendant à ce que RXO se fall dans les 12 prochains mois (un possible changement de -1.39% downside). 36 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour RXO (RXO) ?
La dernière note d'analyste pour RXO (NYSE:RXO) a été fournie par Stifel, et RXO maintenu leur note hold.
Quand a eu lieu la dernière mise à niveau pour RXO (RXO) ?
Il n'y a pas de dernière amélioration pour RXO
Quand a eu lieu la dernière dégradation pour RXO (RXO) ?
La dernière réduction pour RXO Inc a eu lieu le avril 4, 2025 lorsque Oppenheimer a changé leur objectif de prix de N/A à N/A pour RXO Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour RXO (RXO) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de RXO, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour RXO a été déposée le octobre 10, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 10, 2026.
La note d'analyste pour RXO (RXO) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de RXO (RXO) était un maintenu avec un objectif de prix de $14.00 à $17.00. Le prix actuel de RXO (RXO) est de $17.24, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.